Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L de Ridder

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
Alimentary Pharmacology & Therapeutics|November 19, 2010
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limitedC I De Bie, T Z Hummel, A Kindermann, et al.
Mucosal Immunology|August 17, 2019
IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4<sup>+</sup> T cells: relevance to inflammatory bowel diseaseS Veenbergen, P Li, H C Raatgeep, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 4, 2026
Randomized trial comparing 5-year follow-up of first-line infliximab to conventional therapy in paediatric Crohn's diseaseS A Vuijk, M M E Jongsma, M A Cozijnsen, et al.
Journal of Crohn'S & Colitis|June 10, 2014
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's diseaseF M Ruemmele, G Veres, K L Kolho, et al.
Alimentary Pharmacology & Therapeutics|July 10, 2018
Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHANM E Joosse, M A Aardoom, P Kemos, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
Alimentary Pharmacology & Therapeutics|November 19, 2010
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limitedC I De Bie, T Z Hummel, A Kindermann, et al.
Mucosal Immunology|August 17, 2019
IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4<sup>+</sup> T cells: relevance to inflammatory bowel diseaseS Veenbergen, P Li, H C Raatgeep, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 4, 2026
Randomized trial comparing 5-year follow-up of first-line infliximab to conventional therapy in paediatric Crohn's diseaseS A Vuijk, M M E Jongsma, M A Cozijnsen, et al.
Journal of Crohn'S & Colitis|June 10, 2014
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's diseaseF M Ruemmele, G Veres, K L Kolho, et al.
Alimentary Pharmacology & Therapeutics|July 10, 2018
Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHANM E Joosse, M A Aardoom, P Kemos, et al.
Pageof 16